Biotechnology company Cartherics, which is developing immune cell therapies for the treatment of cancer, has entered a collaborative research agreement with TiCARos Co to assess its proprietary CLIP-CAR technology in Cartherics’ induced pluripotent stem cell (iPSC)-derived natural killer (NK) cells.
Privately-held Melbourne-based biotechnology company Cartherics, which is developing immune cell therapies for the treatment of cancer, has been granted US patent 11,400,145, entitled “Genetically modified cells and uses thereof”.